Abstract：Objective To systematically evaluate the efficacy and safety of Magnesium Isoglycyrrhizinate combined therapy in the treatment of chronic hepatitis B. Methods Literatures published in China Biology Medicine (CBM),Wanfang Data, China National Knowledge Infrastructure (CNKI), PubMed, and Cochrane Library from its establishment to October 2020 were searched, randomized controlled trials (RCT) of Magnesium Isoglycyrrhizinate combined therapy in the treatment of chronic hepatitis B was included. The included literatures were screened, extracted and evaluated for quality, and meta-analysis was performed using Review Manager 5.3 software. Results Sixteen RCT studies were included, including 1932 patients, 979 in the experimental group and 953 in the control group. Meta-analysis results showed that the overall efficacy of the experimental group was higher than that of the control group, and the difference was statistically significant (OR=3.34，95%CI=[2.14，5.22]，P＜0.000 01). The levels of alanine aminotransferase (ALT),aspartate aminotransferase (AST) and total bilirubin (TBil) in experimental group decreased more significantly than those in control group, ALT (MD=-17.26, 95%CI=[-22.32, -12.21], P＜0.000 01), AST(MD=-13.62, 95%CI=[-22.20, -5.03], P=0.002), TBil (MD=-4.80, 95%CI=[-6.10, -3.51], P＜0.000 01). The incidence of adverse reactions in experimental group was lower than that in control group, and the difference was statistically significant (OR=0.54, 95%CI=[0.32, 0.91], P=0.02). Conclusion Magnesium Isoglycyrrhizinate combination therapy can significantly reduce the levels of ALT, AST and TBiL in chronic hepatitis B patients, and the adverse reaction rate is lower than that of monotherapy.
曾雪亮；钟文敏；李蓓. 异甘草酸镁联合疗法治疗慢性乙型肝炎的效果及安全性的meta分析[J]. 中国当代医药, 2021, 28(30): 13-17.
ZENG Xue-liang；ZHONG Wen-min；LI Bei. Meta-analysis of efficacy and safety of Magnesium Isoglycyrrhizinate combined therapy in the treatment of chronic hepatitis B. 中国当代医药, 2021, 28(30): 13-17.
京公网安备 11010502046607号